Cushing's Syndrome clinical trials at University of California Health
3 in progress, 1 open to eligible people
A Study of the Efficacy and Safety of Relacorilant in Patients With Endogenous Cushing Syndrome
open to eligible people ages 18-80
This is a Phase 3, double-blind, placebo-controlled, randomized-withdrawal study to assess the efficacy, safety and pharmacokinetics (PK) of relacorilant in patients with endogenous Cushing syndrome and concurrent type 2 diabetes mellitus/impaired glucose tolerance and/or uncontrolled hypertension
at UCLA
SPI-62 as a Treatment for Adrenocorticotropic Hormone-dependent Cushing's Syndrome
Sorry, not currently recruiting here
This is a randomized, placebo-controlled, crossover study of SPI-62 in subjects with ACTH-dependent Cushing's syndrome. Subjects will receive each of the following 2 treatments for 12 weeks: SPI-62 and matching placebo
at UCLA
SPI-62 as a Treatment for Hypercortisolism Related to a Benign Adrenal Tumor
Sorry, not currently recruiting here
This will be a randomized, double-blind study to evaluate the efficacy, safety, and pharmacological effect of SPI-62 in subjects with hypercortisolism related to a benign adrenal tumor.
at UC Irvine UCLA
Our lead scientists for Cushing's Syndrome research studies include Anthony Heaney, MD Qin Yang, MD.
Last updated: